ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on helping patients fight cancer by developing a pipeline of product candidates based on protein engineering and oncology led by the cluster of differentiation 47 (CD47) blocker. It is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), head and neck squamous cell carcinomas (HNSCC), gastric and breast cancer. Its preclinical program is focused on developing ALTA-002, which combines its signal regulatory protein alpha (SIRPa) and toll-like receptor 9 agonist antibody conjugate (TRAAC).

Number of employees : 43 people.
Sales per Business
20202021Delta
Immuno-oncology1.18100%---
USD in Million
Sales per region
20202021Delta
United States and Ireland1.18100%---
USD in Million
Managers
Name Title Age Since
Jaume Pons President, Chief Executive Officer & Director 55 2015
Peter S. García Chief Financial Officer 60 2021
Sophia Randolph, Dr. Director & Chief Medical Officer 53 2021
Michael Chang, Dr. Vice President-Operations - 2015
Hank Stern Vice President-Chemistry, Manufacturing & Controls - 2015
Jeanne Y. Jew Chief Business Officer 58 2020
Susan Vermeir Vice President-Regulatory Affairs - 2020
Shelly Pinto Chief Accounting Officer & Vice President-Finance 45 2021
Members of the board
Name Title Age Since
Corey S. Goodman, Dr. Executive Chairman 69 2015
Rekha Hemrajani Non-Executive Independent Director 51 2020
Jason Lettmann Independent Director 43 2020
Jack Bech Nielsen Independent Director 57 2020
Itziar Canamasas, Dr. Independent Director 47 2022
Jaume Pons President, Chief Executive Officer & Director 55 2015
Sophia Randolph, Dr. Director & Chief Medical Officer 53 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 40,747,065 25,623,767 62.9% 0 0.0% 62.9%
Shareholders
NameEquities%
venBio Partners LLC 9,699,925 23.8%
LSV CAPITAL MANAGEMENT LLC 4,926,963 12.1%
Vivo Capital LLC 4,220,048 10.4%
Fidelity Management & Research Co. LLC 3,985,922 9.80%
Logos Global Management LP 3,011,352 7.40%
SSgA Funds Management, Inc. 2,133,744 5.25%
The Vanguard Group, Inc. 1,302,215 3.20%
Wellington Management Co. LLP 1,128,101 2.77%
Janus Henderson Investors US LLC 918,908 2.26%
Redmile Group LLC 772,397 1.90%
Brand Portfolio
In partnership withAllbrands.markets
More brands of ALX Oncology Holdings Inc.